BridgeBio Pharma Other Non-Current Liabilities 2018-2024 | BBIO
BridgeBio Pharma other non-current liabilities from 2018 to 2024. Other non-current liabilities can be defined as field containing the sum of all non-current liabilities that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
BridgeBio Pharma Annual Other Non-Current Liabilities
(Millions of US $) |
| 2023 |
$9 |
| 2022 |
$27 |
| 2021 |
$22 |
| 2020 |
$10 |
| 2019 |
$4 |
| 2018 |
$0 |
| 2017 |
$ |
BridgeBio Pharma Quarterly Other Non-Current Liabilities
(Millions of US $) |
| 2024-09-30 |
$0 |
| 2024-06-30 |
$0 |
| 2024-03-31 |
$1 |
| 2023-12-31 |
$6 |
| 2023-09-30 |
$12 |
| 2023-06-30 |
$13 |
| 2023-03-31 |
$18 |
| 2022-12-31 |
$27 |
| 2022-09-30 |
$28 |
| 2022-06-30 |
$29 |
| 2022-03-31 |
$27 |
| 2021-12-31 |
$22 |
| 2021-09-30 |
$28 |
| 2021-06-30 |
$13 |
| 2021-03-31 |
$12 |
| 2020-12-31 |
$10 |
| 2020-09-30 |
$13 |
| 2020-06-30 |
$9 |
| 2020-03-31 |
$3 |
| 2019-12-31 |
$4 |
| 2019-09-30 |
$1 |
| 2019-06-30 |
|
| 2019-03-31 |
|
| 2018-12-31 |
|
| 2018-09-30 |
|
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
